Quarterly report · Q2
3583.TEDINET S100S6MI
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥5.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥270m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥341m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥294m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥639m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥366m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥294m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥405m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥218m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥469m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥270m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥218m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥270m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥9.5bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥9.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥9.4bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.5bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥3.5bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥6.0bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥5.8bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.6bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.9bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.8bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.4bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.5bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥601m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥338m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥190m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥99m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥184m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥44m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥139m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥206m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥114m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥78.21 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.64 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥169.17 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥97.39 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥39.08 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 63.1% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.8% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥2.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥2.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥645,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥430m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥721m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥720m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥645,000 |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥48m |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.9bn |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.9bn |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥382m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥645,000 |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥430m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥479m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥696m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥693m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥44m |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥435m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥479m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 520
| Item | Context | Value | Unit |
|---|---|---|---|
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 8504000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 7566000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 40941000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 370797000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 2435227000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 2388065000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 2476169000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 2758862000 | JPY |
| Shipment expenses sga | Prior1YTDDuration | 71435000 | JPY |
| Shipment expenses sga | CurrentYTDDuration | 49815000 | JPY |
| Payrolls allowances and bonuses sga | Prior1YTDDuration | 240278000 | JPY |
| Payrolls allowances and bonuses sga | CurrentYTDDuration | 251833000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 31315000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 35473000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 8577000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 9885000 | JPY |
| Provision for jesop expense sga | Prior1YTDDuration | 10118000 | JPY |
| Provision for jesop expense sga | CurrentYTDDuration | 9470000 | JPY |
| Welfare expenses sga | Prior1YTDDuration | 41295000 | JPY |
| Welfare expenses sga | CurrentYTDDuration | 41565000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 52381000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 54756000 | JPY |
| Rent expenses sga | Prior1YTDDuration | 18014000 | JPY |
| Rent expenses sga | CurrentYTDDuration | 18012000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00584-000TechnologicalProductsReportableSegmentsMember | 1965087000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00584-000MedicalProductsReportableSegmentsMember | 693087000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 2658175000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 2658175000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00584-000TechnologicalProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00584-000MedicalProductsReportableSegmentsMember | 2437000 | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 2437000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 2437000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00584-000TechnologicalProductsReportableSegmentsMember | 1965087000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00584-000MedicalProductsReportableSegmentsMember | 695524000 | JPY |
| Net sales | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 2660612000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 2660612000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00584-000TechnologicalProductsReportableSegmentsMember | 434640000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00584-000MedicalProductsReportableSegmentsMember | 44350000 | JPY |
| Operating income | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 478990000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 478990000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00584-000TechnologicalProductsReportableSegmentsMember | 1902215000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00584-000MedicalProductsReportableSegmentsMember | 720071000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 2622286000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 2622286000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00584-000TechnologicalProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00584-000MedicalProductsReportableSegmentsMember | 645000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 645000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 645000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00584-000TechnologicalProductsReportableSegmentsMember | 1902215000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00584-000MedicalProductsReportableSegmentsMember | 720717000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |